课题基金 / 基金详情

Twenty-second Annual Fanconi Anemia Research Fund Scientific Symposium

Twenty-second Annual Fanconi Anemia Research Fund Scientific Symposium
第二十二届范可尼贫血研究基金年度科学研讨会
批准号:
8062909
负责人:
Grover Carlton Bagby
金额:
$1.92万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-09-17 至 2011-09-16

项目摘要

项目成果

Grover Carlton Bagby的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):第二十二届范可尼贫血研究基金科学研讨会范可尼贫血(FA)是一种罕见的遗传性疾病,其特征是骨髓衰竭、发育异常、骨髓增生异常(MDS)、急性非淋巴细胞白血病(AML)、实体肿瘤和细胞对交联剂过敏。范可尼贫血的一个独特特征是在生命早期发生特异性上皮和造血恶性肿瘤,通常只在老年人群中发现。这些蛋白质的功能在很大程度上是未知的,但它们彼此形成复合物,在一个典型的“途径”中,11种已知的范可尼贫血蛋白中的8种结合在一起,形成一个复合物和单泛素化的FANCD2,其中一种蛋白质不在“核心”复合物中。有体外和体内的证据表明,至少有一些FA蛋白还通过与信号分子形成复合物来促进造血细胞的存活信号通路。干细胞移植是符合条件的骨髓衰竭患者的治疗选择。骨髓衰竭的幸存者最终面临发展成鳞状细胞癌的极高风险。这种疾病是基因治疗的理想候选者,因为补充干细胞固有的选择性。越来越多的证据表明,FA信号通路的功能障碍可以随着非fanconi患者肿瘤细胞的体细胞变化(表观遗传和遗传)而发展,这种体细胞变化的后果抑制了自我复制的潜力,并增强了祖细胞池的衰老。一年一度的范可尼贫血研究基金科学研讨会是一个为期三天的会议,由精选的受邀演讲和大约35个口头摘要演讲(从摘要征集中选择)组成。研讨会汇集了来自世界各地的主要研究人员和医生,以及年轻的研究人员,研究生和研究生,讨论这种罕见疾病的所有基础,转化和临床研究方面。范可尼贫血研究基金积极鼓励和支持学生和初级研究人员的出席和提交。会议为研究人员提供了一个独特的机会来交叉施肥和发展跨学科的研究项目。这些数据不仅将与所有研究人员免费共享,而且还将通过在线生物信息工具GeneSifter提供这些文件。本申请为定于2010年10月在明尼苏达州明尼阿波利斯举行的会议寻求部分支持。
英文摘要
DESCRIPTION (provided by applicant): Twenty-second Annual Fanconi Anemia Research Fund Scientific Symposium Fanconi anemia (FA) is a rare hereditary disease characterized by bone marrow failure, developmental anomalies, a high incidence of myelodysplasia (MDS), acute non-lymphocytic leukemia (AML), solid tumors, and cellular hypersensitivity to cross-linking agents. A unique feature of Fanconi anemia is the development, in early life, of specific epithelial and hematopoietic malignancies usually found only in aging populations. The function of the proteins is largely unknown but many form complexes with each other and in one canonical "pathway," eight of the eleven known Fanconi anemia proteins bind together in a complex and monoubiquitinate FANCD2, one of the proteins not in the "core" complex. There is in vitro and in vivo evidence that at least some of the FA proteins also promote survival signaling pathways in hematopoietic cells by forming complexes with signaling molecules. Stem cell transplantation is the treatment of choice for eligible patients with bone marrow failure. Survivors of bone marrow failure ultimately face an extremely high risk of developing squamous cell cancers. The disease is an ideal candidate for gene therapy because of the inherent selectability of complemented stem cells. Broad evidence is being developed that dysfunction of the FA signaling pathways can develop as somatic changes (epigenetic and genetic) in neoplastic cells arising in non-Fanconi patients and that the consequences of such somatic changes suppress self-replicative potential and enhance senescence in progenitor cell pools. The Annual Fanconi Anemia Research Fund Scientific Symposium is a three-day conference comprised of select invited presentations and approximately 35 oral abstract presentations (to be chosen from a call for abstracts) in a single-track format. The Symposium brings together leading researchers and physicians as well as young investigators, graduate and post-graduate students from around the world to discuss all basic, translational, and clinical research aspects of this rare disease. The Fanconi Anemia Research Fund actively encourages and supports attendance and submissions by students and junior investigators. The meeting provides a unique opportunity for investigators to cross-fertilize and develop interdisciplinary research projects. Not only will the data be shared freely with all investigators, the files will be made accessible through GeneSifter, an online bio-information tool. This application seeks partial support for this meeting, scheduled to be held in Minneapolis, Minnesota in October 2010. PUBLIC HEALTH RELEVANCE: Twenty-second Annual Fanconi Anemia Research Fund Scientific Symposium The Fanconi Anemia Research Fund's Annual Symposia are the only scientific conferences convened that focus on Fanconi anemia (FA). The research focus of FA investigators is broad and goes far beyond a narrow focus on a rare disease. Recent research has established the importance of Fanconi anemia genes in tumor suppression, DNA repair, stem cell function, and suppression of apoptosis and senescence, survival, leukemogenesis and carcinogenesis, and genetic instability - topics highly relevant to DKUHD, NIDDK areas of scientific interest. Advances made in FA science have an impact beyond affected patients and families. Acquired abnormalities of FA genes and FA gene expression have been reported in patients with sporadic malignancies of plasma cells, leukemia, head and neck cancer, lung cancer, and ovarian cancer. The Scientific Symposium brings together populations of investigators that would benefit from cross-talk but do not typically or consistently interact. Its relatively small scale and concentrated focus promotes interaction and collaboration between participants across the globe. The meeting provides an excellent training environment for junior investigators and trainees.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
24th Annual Fanconi Anemia Research Fund Scientific Symposium
23rd Annual Fanconi Anemia Research Fund Scientific Symposium
Fanconi Anemia: Molecular pathogenesis of Bone Marrow Failure and Clonal Evolutio
  • 批准号:
    8255538
  • 项目类别:
  • 资助金额:
    $30.17万
  • 财政年份:
    2011
  • 负责人:
    Grover Carlton Bagby
  • 依托单位:
Fanconi Anemia: Molecular pathogenesis of Bone Marrow Failure and Clonal Evolutio
  • 批准号:
    7918661
  • 项目类别:
  • 资助金额:
    $49.63万
  • 财政年份:
    2010
  • 负责人:
    Grover Carlton Bagby
  • 依托单位:
国内基金
海外基金
二次谐波非线性光学显微成像用于前列腺癌的诊断及药物疗效初探
  • 批准号:
    30470495
  • 项目类别:
    面上项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2004
  • 负责人:
    邓小元
  • 依托单位:
电极/溶液界面上分子取向电位调控的准确测量
  • 批准号:
    20373076
  • 项目类别:
    面上项目
  • 资助金额:
    27.0万元
  • 批准年份:
    2003
  • 负责人:
    王鸿飞
  • 依托单位: